Borderline Personality Disorders Clinical Trials, Growth, and Key Companies |Companies – Oryzon, Boehringer Ingelheim, Otsuka, Intra-Cellular Therapies.

Advertisements
DelveInsight Business Research LLP
(Las Vegas Nevada United States),DelveInsight’s ”Borderline Personality Disorders – Pipeline Insight, 2023,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Borderline Personality Disorders pipeline landscape.

(Las Vegas Nevada United States),DelveInsight’s ”Borderline Personality Disorders – Pipeline Insight, 2023,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Borderline Personality Disorders pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Borderline Personality Disorders Pipeline Report

Over 5+ Companies and 5+ Pipeline Drugs for Borderline Personality Disorders are in various stages of development, and their anticipated acceptance in the Borderline Personality Disorders market would significantly increase market revenue. 
Leading Borderline Personality Disorders companies developing novel drug candidates to improve the Borderline Personality Disorders treatment landscape include Oryzon, Boehringer Ingelheim, Otsuka, Intra-Cellular Therapies, and others.
Promising Borderline Personality Disorders pipeline therapies in various stages of development include Vafidemsta and others.

Borderline Personality Disorders Overview

The term ‘Borderline Personality Disorder’ (BPD) refers to a psychiatric syndrome that is characterized by emotion dysregulation, impulsivity, risk-taking behavior, irritability, feelings of emptiness, self-injury, and fear of abandonment, as well as unstable interpersonal relationships. Paranoid ideation and dissociative states are also transient features of the syndrome. Moreover, many patients with BPD show recurring self-injurious or suicidal behavior. BPD has a lifetime prevalence of about 6%. It is much more common in clinical settings, thus rendering BPD highly relevant for health care providers and public health in general.

Borderline Personality Disorders Pipeline Analysis: Drug Profile

Vafidemstat: Oryzon

Vafidemstat (ORY-2001) is an oral small molecule that has been optimized for CNS indications and that acts as a covalent inhibitor of the epigenetic enzyme Lysine Specific Demethylase-1, LSD1 (KDM1A). Oryzon has performed a Phase IIa clinical trial (REIMAGINE study) to assess vafidemstat’s effects on agitation-aggression in patients with different psychiatric disorders: Autism Spectrum Disorder (ASD), Borderline Personality Disorder (BPD) and adult Attention Deficit Hyperactivity Disorder (ADHD).

Discover more about the emerging Borderline Personality Disorders drugs @ Borderline Personality DisordersTreatment Drugs

Borderline Personality Disorders Pipeline Therapies and Key Companies

Vafidemstat: Oryzon

And many others 

Borderline Personality Disorders Pipeline Therapeutics Assessment

This segment of the report provides insights about the Borderline Personality Disorders drugs segregated based on the following parameters that define the scope of the report, such as:

DelveInsight’s Report covers around 5+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

 

Route of Administration

Borderline Personality Disorders pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

Small molecule
Cell Therapy
Peptides
Polymer
Small molecule
Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination, and Mono/Combination.

Scope of the Borderline Personality Disorders Pipeline Report 

Coverage: Global 
Key Borderline Personality Disorders Companies: Oryzon, Boehringer Ingelheim, Otsuka, Intra-Cellular Therapies, and others.
Key Borderline Personality Disorders Pipeline Therapies:  Vafidemsta and others

Find out more about the Borderline Personality Disorders treatment options in development @ Borderline Personality Disorders Clinical Trials

Table of Contents

1. Borderline Personality Disorders Introduction

2. Borderline Personality Disorders Executive Summary

3. Borderline Personality Disorders Overview

4. Borderline Personality Disorders Pipeline Therapeutics

5. Borderline Personality Disorders Late-Stage Products (Phase III)

6. Borderline Personality Disorders Mid-Stage Products (Phase  II)

7. Borderline Personality Disorders Early Stage Products (Phase  I/II)

8. Borderline Personality Disorders  Preclinical Stage Products

9. Borderline Personality Disorders Discovery Stage Products

10. Borderline Personality Disorders Therapeutic Assessment

11. Borderline Personality Disorders Inactive Products

12. Borderline Personality Disorders Collaborations Assessment- Licensing / Partnering / Funding

13. Borderline Personality Disorders Unmet Needs

14. Borderline Personality Disorders Market Drivers and Barriers

15. Appendix

16. About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Daily Digest Signup

Daily business and market business news, business management tips, market research insights, and more.

Advertisements

Smart public opinion research for everyone.

%d bloggers like this: